Temozolomide Capsule
Product Images NDC 16571-821

Each capsule of NDC 16571-818-51 contains 100mg of Temozolomide, USP which is a cytotoxic agent manufactured by Rising Pharma Holdings, Inc. The package insert includes recommendations for the appropriate use of Temozolomide varying capsule strengths in Capsules, USP to establish a daily regimen. The drug should be dispensed in tight, light-resistant containers as defined in USP/NF, and should be stored at 25°C (77°F) with allowed excursions to 15° to 30°C (59° to 86°F). The accompanying directions should be read fully before use. Made in India.*

This is a description of a medication with the NDC code 16571-819-51 containing 140mg of Temozolomide, manufactured by Rising Pharma Holdings, Inc. in East Brunswick, NJ. The recommended dosage is not provided, but can be found in the package insert. It is a cytotoxic agent and should be administered orally with caution. It should be stored in tight, light-resistant containers at room temperature. It has been manufactured in India and the packaging has a Code: TS/DRUGS/24/2015 and was issued in April 2022.*

This is a description of a medication with the NDC code 16571-820-51, which contains 180mg of Temozolomide, a cytotoxic agent used for cancer treatment. It is manufactured by Rising Pharma Holdings, Inc. and dispensed in capsules, USP. The usual dose is to be determined by following the package insert guidelines. The directions for administration should be carefully followed, and caution should be exercised as it is a cytotoxic agent. It should be stored in tight, light-resistant containers between 15°C to 30°C (59°F to 86°F). The text also includes other technical information such as code, issuance date, and controlled room temperature guidelines.*

Each capsule of 'Rising' NDC 16571-817-51 contains 20 mg of Temozolomide, a cytotoxic agent used in establishing a daily regimen. The package insert provides recommendations for the use of varying capsule strengths. The capsules should be dispensed in tight, light-resistant containers as defined in USP/NF and stored at 25°C (77°F) with excursions permitted to 15° to 30°C (59° to 86°F). Read accompanying directions carefully before using this product.*

This is a description of medication, Temozolomide capsules used for oral administration which is a cytotoxic agent requiring special handling. Each capsule contains 250 mg of Temozolomide, USP. The usual dose is mentioned in the package insert. This medication should be dispensed in tight, light-resistant containers and stored at a controlled room temperature. The manufacturing company is Rising Pharma Holdings located in East Brunswick, NJ.*

Each capsule of PERising woc16571-816-51 contains 5 mg Tamozolomids, USP pharmaceutical ingredient. The medication is manufactured by Rising Pharma Holdings Inc., located in East Brunswick, NJ 08816. It is a cytotoxic agent, and caution must be taken while handling and storing it. The medication is dispensed for oral administration, and it is contained in special vessels according to the United States Pharmacopeia/ National Formulary guidelines. The container must be stored between 15 to 30°C, with a specified permitted range of temperature excursions, and must be protected from light. Further information about administration and dosage can be found in the package insert.*

This appears to be a statistical analysis output for a clinical trial. The ITT population (which likely stands for "intent-to-treat") is being evaluated for overall survival. The hazard ratio (HR) is 0.63 with a confidence interval of 0.52 to 0.75, and the log-rank P-value is less than 0.0001. The numbers 12, 16, 220, 2, 28, 32, and 36 likely correspond to some sort of time intervals.*